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Abstract
Exogenous application of recombinant TIMP-1 protein
modified by addition of a glycosylphosphatidylinositol
(GPI) anchor allows efficient insertion of the fusion pro-
tein into cell membranes. This ‘cell surface engineering’
leads to changes in the proteolytic environment. TIMP-
1-GPI shows enhanced as well as novel in vitro biological
activities including suppression of proliferation, reduced
migration, and inhibition of invasion of the colon carci-
noma cell line SW480. Treatment of SW480 tumors
implanted in Rag (-/-) common g chain (-/-) C57BL/6
mice with peritumorally applied TIMP-1-GPI, control
rhTIMP-1 protein, or vehicle shows that TIMP-1-GPI
leads to a significant reduction in tumor growth.
Keywords: colorectal cancer; matrix
metalloproteinases; proliferation; TIMP-1-GPI;
tissue inhibitors of metalloproteinases.
The matrix metalloproteinases (MMPs) are a family of
zinc-containing endopeptidases that degrade compo-
nents of the extracellular matrix (ECM) and also regulate
various cellular functions through their post-translational
modification (cleavage) of proteins (Nagase et al., 2006).
The MMPs are represented by collagenases, gelatinases,
stromelysins, and membrane-type MMPs (Visse and
Nagase, 2003; Nagase et al., 2006). These enzymes
have also been implicated in multiple stages of cancer
progression, including the acquisition of an invasive
phenotype and tumor proliferation. In colon carcinoma,
expression of MMP-2, MMP-9, and MMP-7 have been
associated with the general aggressiveness of the tumor
(Matsuyama et al., 2002; Rath et al., 2006; Oshima et al.,
2008). The increased expression of MMP-2 and MMP-9
has been linked to enhanced invasion, migration, and
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attachment of the colon carcinoma cell line SW480
(Murray et al., 2004). In contrast to other MMP family
members, MMP-7 is usually overproduced by carcinoma
cells as opposed to stromal cells and thus an involve-
ment of this proteinase in tumorigenesis including that of
colorectal cancer has been proposed (Yoshimoto et al.,
1993; Cockett et al., 1994; Nagashima et al., 1997).
MMP activities are regulated at multiple levels, includ-
ing endogenous inhibitors – the tissue inhibitors of metal-
loproteinases (TIMP-1, TIMP-2, TIMP-3, and TIMP-4)
(Maskos and Bode, 2003). The balance between MMP
and TIMP expression helps dictate ECM turnover and
remodeling in normal tissue homeostasis and pathogen-
esis, and also moderates the regulatory functions of
MMPs (Visse and Nagase, 2003; Nagase et al., 2006).
The TIMP proteins have also been shown to have addi-
tional biological functions not directly attributed to MMP
inhibition (Chirco et al., 2006; Nagase et al., 2006). These
include the regulation of apoptosis, cell proliferation, and
aspects of angiogenesis. We have previously demon-
strated that the bioactivities of TIMPs can be altered by
changing their cellular distribution (Djafarzadeh et al.,
2004, 2006, 2009). The modification of TIMP-1 protein
by the addition of a glycosylphosphatidylinositol (GPI)
anchor allows the protein to be efficiently transferred from
one cell surface to another (Medof et al., 1996). Exo-
genous application of recombinant TIMP-1-GPI fusion
protein leads to efficient incorporation of TIMP-1 into cell
surface membranes. This surface engineering with TIMP-1-
GPI has been shown to lead to enhanced as well as
novel biological activities (Djafarzadeh et al., 2004, 2006,
2009).
We have previously identified a series of potential anti-
tumor effects moderated by treatment with TIMP-1-GPI
in an in vitro setting, including the sequestering of MMPs
on the cell surface, reduced tumor secretion of MMPs, a
dose-dependent inhibition of renal cell carcinoma prolif-
eration, migration, invasion, and an increase in the sen-
sitivity of the tumor cells to FAS-mediated apoptosis
(Djafarzadeh et al., 2006, 2009). In the present study, we
sought to verify a select set of these effects in vitro in a
colon carcinoma cell line, and to then determine if these
beneficial effects on tumor growth could also be reiter-
ated in an in vivo setting. We specifically sought to evalu-
ate the potential influence of peritumoral administration
of the agent on tumor growth. This was performed in the
absence of an adaptive immune response wRag2 g chain
(-/-) micex (Shinkai and Alt, 1994) to exclude potential T
cell suppression of tumor growth (Djafarzadeh et al.,
2006).
The colon adenocarcinoma, grade III–IV tumor cell line
SW480, was used as the model system (Murray et al.,
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2004). The effects of treatment of the cells were first veri-
fied in vitro. The incorporation of recombinant TIMP-1-
GPI protein into the cell membrane of SW480 cells was
tested by incubation with 14 ng/ml of purified TIMP-1-
GPI, recombinant human rhTIMP-1 control protein or
vehicle for 1 h at 378C. Surface-associated TIMP-1 pro-
tein was detected using human specific TIMP-1 mono-
clonal antibody and fluorescence-activated cell sorting
(FACS) (Djafarzadeh et al., 2006). Addition of vehicle or
control rhTIMP-1 did not lead to a change in the FACS
shift; however, GPI-anchored TIMP-1 resulted in a strong
surface signal for TIMP-1 (Figure 1A).
The dose-dependent effect of an increasing surface
level of TIMP-1 on the constitutive release of MMPs from
the SW480 cells was evaluated (Figure 1B and C). Secre-
tion of MMP-9 and MMP-2 protein from the SW480 cells
was tested by gelatinase zymography (Klier et al., 2001;
Djafarzadeh et al., 2004). The cells produced low but
detectable levels of MMP-9 but undetectable levels of
MMP-2. rhTIMP-1 protein at 14 ng/ml had no effect on
MMP-9 secretion. In contrast, starting at 0.875 ng/ml,
TIMP-1-GPI treatment led to a concentration-dependent
decrease of MMP-9 release into the growth media (Figure
1B). In the experiments presented, the growth media
was pretreated with 1 mM p-aminophenylmercuric ace-
tate (APMA) to induce activation of proMMP-9 to MMP-9
for better quantification. Parallel zymography experi-
ments demonstrated that the secreted enzyme was
primarily the pro-form of the enzyme (data not shown).
MMP-7 plays multiple roles in the invasion and meta-
stasis of carcinoma cells (Strand et al., 2004; Mylona et
al., 2005). The cleavage of cell surface proteins other
than ECM components by this metalloproteinase may
also contribute to its tumorigenic effects. For example,
MMP-7 has been shown to promote the activation of the
epidermal growth factor (EGF) receptor by inducing the
release of an EGF ligand (Mimori et al., 2004).
The secretion of MMP-7 from SW480 was tested by
Western blot analysis of the growth media using mono-
clonal antibodies directed against human MMP-7. Cul-
ture media (serum-free) were taken 24 h after either no
treatment of SW480, treatment with vehicle, 14 ng/ml of
either rhTIMP-1 or TIMP-1-GPI or equal molar concen-
trations of GPI-anchor/phosphatidylserine, and then test-
ed for the presence of MMP-7. The results show that
TIMP-1-GPI blocked the secretion of MMP-7 by SW480
cells (Figure 1C). Thus, analogous to what was found for
MMP-9 in the zymography assay, GPI-anchored TIMP-1
protein was found to reduce the secretion of MMP-7 into
the growth media.
The reduced secretion of MMP-9 and MMP-7 sug-
gested a potential sequestering of the proteins on the cell
surface. FACS analysis using MMP-9 and MMP-7 spe-
cific monoclonal antibodies showed an increased signal
for the proteins on the cell surface following treatment
with 7 or 14 ng/ml TIMP-1-GPI (Figure 1D) but not with
recombinant hTIMP-1 or denatured TIMP-1-GPI (14 ng/
ml), with vehicle or with GPI-anchor/phosphatidylserine
control (data not shown). The protein appeared to remain
on the cell surface as the surface detection of TIMP-1-
GPI by FACS remained over a 72 h period (Figure 1E).
Additional control qPCR studies were performed (as
described in Djafarzadeh et al., 2006) to determine if the
suppressive effect of TIMP-1-GPI on MMP-7 or MMP-9
protein secretion could be explained in part by decreased
gene expression. The results showed that mRNA levels
were either largely unchanged (MMP-7) or were increased
(MMP-9) with TIMP-1-GPI treatment at 24 h (data not
shown).
We have previously shown that treatment with TIMP-
1-GPI can either enhance or suppress cell proliferation
depending on the specific cell type studied (Djafarzadeh
et al., 2004). To assess the effect of TIMP-1 surface engi-
neering on the proliferation of SW480 cells, MTT assays
were performed (Djafarzadeh et al., 2006). The exoge-
nously added TIMP-1-GPI protein was found to elicit a
dose-dependent decrease in the proliferation of SW480
(Figure 2A).
A reduction in the secretion of MMP-7 and MMP-9
suggests a reduced capacity of the SW480 cell line to
undergo ECM invasion. The effect of TIMP-1-GPI vs.
rhTIMP-1 treatment on the ability of SW480 cells to
invade Matrigel was measured using induced migration
to fetal calf serum (FCS) (Biocrom, Berlin, Germany), vas-
cular endothelial growth factor (VEGF) (R&D systems,
Minneapolis, USA), and EGF (Biochrom, Berlin, Germany)
using a modified Boyden chamber (Djafarzadeh
et al., 2004, 2006). Cells which had undergone migra-
tion to the bottom of the insert were detached, lysed,
and detected by CyQuant dye as described previously
(Djafarzadeh et al., 2004, 2006). Optimal SW480 migration/
invasion was observed at 10% FCS, 4 ng/ml VEGF, and
4 ng/ml EGF (data not shown). The effect of treatment
with 2–14 ng/ml TIMP-1-GPI and with 14 ng/ml control
rhTIMP-1 on SW480 invasion through Matrigel was then
determined. The maximal migration to FCS, VEGF, and
EGF were each set as 0% inhibition. 100% inhibition of
migration was set to the migration level obtained with
unstimulated SW480 cells. The resultant effect of rhTIMP
or TIMP-1-GPI treatment on migration was calculated as
percent change in the ‘maximal’ value (Figure 2B). Treat-
ment of the SW480 cells with increasing amounts of
TIMP-1-GPI showed a dose-dependent suppression of
invasion, while no effect was observed with rhTIMP-1
control protein.
The in vitro results suggested that in vivo treatment of
a tumor environment with TIMP-1-GPI may directly influ-
ence tumor biology by reducing tumor proliferation and
suppressing invasion into surrounding tissue. This was
tested by the transplantation of SW480 tumors into
immunodeficient mice.
SW480 cells were implanted under the skin of Rag (-/-)
common g chain (-/-) C57BL/6 mice and the growth
characteristics of the tumor established by monitoring
growth by palpation. When the tumor size had reached
approximately 0.5 cm in diameter, the animals were ran-
domized into three groups and therapy was initiated.
Peritumoral injection of 100 ml of TIMP-1-GPI at 14 ng/
ml, 14 ng/ml of control rhTIMP-1 protein or vehicle
(1=phosphate buffered saline, PBS, 0.025% Triton X-
100H) was applied. The injections were made every other
day around the tumor (4 times 25 ml each) for a total of
five treatments over a span of 10 days. One day following
the last treatment, the animals were sacrificed and the
tumor size measured. The results show that treatment
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Figure 1 Incorporation of TIMP-1-GPI into SW480 cells and subsequent effect on MMP-9 and MMP-7 secretion.
The TIMP-1-GPI protein was produced, purified, and quantified as previously described (Djafarzadeh et al., 2004). The vehicle for all
studies was 1=PBS with 0.025% Triton X-100H. SW480 cells (ATCC, Manassis, UT, USA; no. CCL-228) were cultured in Dulbecco’s
modified Eagle’s medium with Glutamax-1 (Gibco-BRL/Life Technologies GmbH, Eggenstein, Germany) supplemented with 7.5%
FCS. To demonstrate reincorporation of TIMP-1-GPI protein into cell membranes, 14 ng/ml of TIMP-1-GPI, or control rhTIMP-1, was
added to SW480 cells as described previously (Djafarzadeh et al., 2006). (A) TIMP-1 was detected on the cell surface by FACS
analysis (Klier et al., 2001). Gray histograms represent isotype control stain; solid line histograms represent TIMP-1 antibody staining.
(B) Gelatinase zymography (Djafarzadeh et al., 2004) showed that secretion of MMP-9 from SW480 was blocked by treatment with
increasing levels of TIMP-1-GPI. Culture media (serum-free) were taken 48 h after treatment of SW480 with 14 ng/ml of rhTIMP-1,
TIMP-1-GPI, phosphatidylserine, or denatured TIMP-1-GPI and compared to untreated control cells and medium and analyzed by
gelatinase zymography (Djafarzadeh et al., 2004). Before analysis, culture supernatants were pretreated with 1 mM APMA to induce
activation of MMP-9 prior to loading on the gel. The band intensities were quantified using ImageJ (http://rsbweb.nih.gov/ij/). (C)
Western blot using monoclonal antibody directed against human MMP-7 (Thermo Scientific, Fremont, CA, USA) was used to detect
secretion from SW480 essentially as described previously (Djafarzadeh et al., 2006). Culture media (serum-free) were taken 24 h after
treatment of SW480 with 14 ng/ml of rhTIMP-1, TIMP-1-GPI, phosphatidylserine, or denatured TIMP-1-GPI and compared to untreat-
ed control cells and medium. Lane loading was adjusted by monitoring absolute cell numbers and volume of growth media used.
The detection antibody was a polyclonal rabbit anti-mouse-HRP (Dako, Glostrup, Denmark; diluted 1:5000). (D) FACS analysis shows
a corresponding increase in surface expression of MMP-9 and MMP-7 following treatment with either 7 ng/ml or 14 ng/ml TIMP-
1-GPI. Control experiments using equal molar concentrations of GPI-anchor/phosphatidylserine, denatured TIMP-1-GPI (14 ng/ml),
or vehicle did not lead to an increase in median channel fluorescence (data not shown). (E) The surface signal for TIMP-1-GPI (14
ng/ml) observed with FACS was stable for up to 72 h.
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Figure 2 The GPI-anchored TIMP-1 suppresses proliferation of
SW480 cells and inhibits tumor invasion.
The effect of cell surface engineering with TIMP-1-GPI on
SW480 invasion through the Matrigel basement membrane
model was assessed. Optimal invasion of the SW480 cells in
response to 10% FCS, 4 ng/ml EGF, or 4 ng/ml VEGF were set
to ‘zero’, and the 100% inhibition value was set to the migration
level observed with untreated SW480 cells (Djafarzadeh et al.,
2004). 5=103 SW480 cells per 100 ml medium were cultured in
96-well microtiter plates for 24 h under standard conditions to
yield firmly attached and stably growing cells (Djafarzadeh et al.,
2006). The SW480 cells were then pretreated with 2, 4, 6, 8, 10,
12, and 14 ng/ml of TIMP-1-GPI or 14 ng/ml of rhTIMP-1 as
described previously (Djafarzadeh et al., 2006). After 1 h the cells
were washed. (A) The effect of increasing levels of TIMP-1-GPI
or rhTIMP-1 control protein on the proliferation of SW480 was
measured using an MTT assay (Djafarzadeh et al., 2006). MTT
was added after 24 h, 48 h, or 72 h as indicated. (B) The effect
on the ability of SW480 to invade Matrigel was measured using
a modified Boyden chamber as described earlier (Djafarzadeh
et al., 2004, 2006).
Figure 3 Effect of peritumoral application of TIMP-1-GPI on
tumor growth.
Immunodeficient Rag (-/-) common g chain (-/-) C57BL/6 mice
were inoculated with SW480 human colonic cancer cells at the
upper dorsal aspect of the vertebral column under anesthesia.
The effect of peritumoral and tumoral TIMP-1-GPI, rhTIMP-1, or
vehicle treatment of the tumor was assessed. Tumor volumewas
detected using a caliper gauge (Helio-Point; Helios, Niedernhall,
Germany). Measurement was performed in all three dimensions.
The volume was then determined using the elongated ellipse
method formula: Vslength=width=heightqpi/6. Statistical anal-
ysis was performed using the software SPSS version 16 (SPSS,
Chicago, IL, USA). After normal distribution of the values was
tested with the Kolmogorov-Smirnov test, the Student t-test was
performed to test the differences between each of the three
groups. Data are the mean of quadruplicate determinations and
95% confidence interval. Each experiment was repeated at least
three times.
with TIMP-1-GPI, but not with rhTIMP-1 or vehicle, lead
to a profound reduction in tumor growth (Figure 3).
Cell surface engineering with TIMP-1-GPI has been
shown to suppress renal cell carcinoma proliferation,
migration, and invasion in vitro (Djafarzadeh et al., 2006).
It is known that the tumor stroma can have a profound
influence on the growth of tumors (Cox and O’Byrne,
2001; McCawley and Matrisian, 2001; Almholt and John-
sen, 2003). The effect of peritumoral application of TIMP-
1-GPI on the growth of colon carcinoma was assessed
using a transplanted colon carcinoma tumor cell model
implanted into Rag (-/-) common g chain (-/-) Balb/c
mice. Application of TIMP-1-GPI in the absence of an
adaptive immune response led to a significant reduction
in tumor growth, while treatment with control rhTIMP-1
did not show a significant effect. These results provide
further evidence that cell surface engineering with GPI-
anchored TIMP-1 leads to enhanced and unique activi-
ties, and that the GPI-anchored recombinant agent may
represent a potential agent for therapeutic application,
e.g., in the context of surgical resection to limit tumor
regrowth.
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